poisar

Stocks · News reference

GSK Affirms FY2026 Adj EPS Guidance of $4.90-$5.00 vs $4.79 Est; Affirms FY2026 Sales Guidance of $44.754B vs $45.690B Est

BenzingaJul 28, 2026, 11:19 AMBenzinga Newsdesk

GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.79 analyst estimate. Affirms FY2026 sales outlook from $44.754 billion to $44.754 billion vs $45.690 billion estimate.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Jul 28, 2026, 11:19 AM
Checked
Jul 28, 2026, 11:19 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading